GlassScriptPhysician profile
Gerardo A Gamez
NPI 1245240829
$24,466.82
in general payments reported to CMS, 2019-2025
71 companies · $5,224 in 2025
The $5,224 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,290 · 2020: $1,366 · 2021: $3,107 · 2022: $3,643 · 2023: $4,546 · 2024: $4,291 · 2025: $5,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $23.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,037.05 |
| Education | $23.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,939.45 | 2021-2025 | |
| Emd Serono, INC. | $1,385.23 | 2019-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $1,357.24 | 2019-2025 | Zilbrysq, Fintepla, Briviact |
| Teva Pharmaceuticals USA, INC. | $1,096.42 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $1,080.38 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $1,006.05 | 2019-2025 | Nuplazid |
| Genzyme Corporation | $984.76 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $940.43 | 2019-2024 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $780.94 | 2019-2025 | |
| Lundbeck LLC | $739.12 | 2020-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $734.54 | 2020-2025 | Ingrezza, Ongentys |
| Genentech USA, INC. | $726.19 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Lilly USA, LLC | $690.52 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Biogen, INC. | $683.38 | 2019-2025 | Vumerity, Tysabri |
| Ge Healthcare | $586.29 | 2019-2025 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $487.48 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $474.77 | 2020-2025 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $414.63 | 2021-2025 | Zeposia |
| Eisai INC. | $377.17 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $376.24 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Sk Life Science, INC. | $373.00 | 2022-2025 | Xcopri |
| Otsuka America Pharmaceutical, INC. | $372.07 | 2023-2025 | Nuedexta, Rexulti |
| Allergan, INC. | $366.23 | 2019-2022 | |
| Horizon Therapeutics Plc | $333.75 | 2022-2023 | Uplizna |
| Pfizer INC. | $311.65 | 2023-2025 | |
| Csl Behring | $305.56 | 2019-2025 | Hizentra |
| Celgene Corporation | $287.13 | 2021-2025 | Zeposia |
| Catalyst Pharmaceuticals, INC. | $284.09 | 2020-2025 | Firdapse |
| Sunovion Pharmaceuticals INC. | $264.87 | 2019-2022 | |
| Tg Therapeutics, INC. | $234.25 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $225.95 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Sumitomo Pharma America, INC. | $217.27 | 2023 | Aptiom |
| Mdd US Operations, LLC | $213.37 | 2019-2025 | Qelbree, Gocovri |
| Revance Therapeutics, INC. | $206.13 | 2024 | Daxxify |
| Biohaven Pharmaceuticals, INC. | $200.54 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.04 | 2022-2025 | Hyqvia |
| Janssen Biotech, INC. | $169.89 | 2025 | |
| Upsher-Smith Laboratories LLC | $159.40 | 2022-2023 | |
| Livanova USA, INC. | $146.88 | 2019 | |
| Avion Pharmaceuticals | $133.31 | 2021-2023 | Dhivy |
| Adamas Pharmaceuticals, INC. | $132.54 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $129.72 | 2022-2023 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $128.39 | 2019-2022 | |
| Grifols USA, LLC | $116.18 | 2019-2025 | Gamunex-C |
| Abbott Laboratories | $103.73 | 2022 | |
| Kyowa Kirin, INC. | $98.30 | 2021-2024 | Nourianz |
| Octapharma USA, INC. | $93.73 | 2022-2025 | Panzyga |
| Tanabe Pharma America, INC. | $78.05 | 2024 | |
| Alnylam Pharmaceuticals INC. | $70.13 | 2019-2023 | Onpattro |
| Jazz Pharmaceuticals INC. | $69.42 | 2024-2025 | |
| Corium, LLC | $69.03 | 2022-2023 | Adlarity |
| Biohaven Pharmaceutical Holding Company LTD. | $56.87 | 2022 | |
| Acorda Therapeutics, INC | $56.10 | 2019-2023 | Inbrija |
| Avanir Pharmaceuticals, INC. | $53.53 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $36.63 | 2023-2025 | Andexxa, Wainua |
| Grt US Holding, INC. | $33.53 | 2022 | |
| Amicus Therapeutics, INC. | $29.00 | 2025 | |
| Janssen Pharmaceuticals, INC | $28.89 | 2021-2022 | |
| Insightec,INC | $27.68 | 2023 | Exablate |
| Aprecia Pharmaceuticals, LLC | $24.18 | 2022 | |
| Mallinckrodt Hospital Products INC. | $23.20 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $21.55 | 2023 | Dysport |
| Medtronic, INC. | $20.43 | 2024 | Intellis Adaptivestim |
| C2n Diagnostics, LLC | $18.77 | 2025 | Precivityad2 |
| Advanced Respiratory, INC | $17.12 | 2020 | |
| Almatica Pharma LLC | $15.85 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.14 | 2020 | |
| Zyla Life Sciences, INC. | $15.06 | 2020 | |
| Mylan Specialty L.P. | $14.84 | 2023 | Glatiramer Acetate |
| Greenwich Biosciences, INC. | $14.10 | 2020 | |
| Portola Pharmaceuticals, LLC | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Gamez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.